Gubra’s first quarter was defined by the landmark exclusive global license agreement with AbbVie for GUBamy, a long-acting amylin analogue for obesity treatment.

AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing a long-acting amylin analogue from Denmark's Gubra in a deal valued at more than $2.2 billion.

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

Introduction & Market Context. Gubra AS (NASDAQ COPENHAGEN:GUBRA) presented its first quarter 2025 results on May 9, highlighting a transformative partnership with AbbVie (NYSE: ABBV) and progress in ...